He X, Li G, Zhu J
Cancer Research Institute, Xiang-Ya School of Medicine, Central South University, China.
J Exp Clin Cancer Res. 2004 Dec;23(4):607-15.
Peripheral blood mononuclear cells (PBMCs) of patients with NPC were immunized in vitro by anti-NPC monoclonal antibody FC2 and transformed by Epstein-Barr virus (EBV). Detection showed that of 10 NPC patients, 8 patients' B cells immunized by FC2 and transformed by EBV produced anti-idiotypic antibodies to NPC. Five types of VH genes and 7 types of VL genes were obtained by RT-PCR amplification and then connected with (Gly4Ser)3 linker to form 14 types of scFv genes. ScFv genes digested with Sfi I were cloned into vector fUSE5 and transformed into E. coli MC 1061. Phage anti-idiotypic antibody library with 1.5 x 10(8) clones was obtained. After four rounds of panning, 270 phage clones were selected randomly and 91 FC2-positive clones were obtained by Sandwich ELISA, the positive ratio was 33.7%. 5 clones (D83, E92, G22, I50, I54), which might display beta type Ab2 scFv, were selected by binding inhibition test. These 5 phage anti-idiotypic antibodies were further analyzed by DNA sequencing. The VDJ regions of G22, I50, I54 belonged to VH4-39-D4-11-JH3-linker-V1-19-JL2, VH4-4-D4-11-JH6 and VH4-31-D4-11-JH6, respectively. E92 had the same VDJ regions with G22; D83 had the same VDJ regions with 150. So, a strategy for preparing and selecting beta type Ab2 scFv or CDR by means of immunization in vitro, EBV transformation and phage display technique is feasible, which paves a way for preparing cancer vaccine using beta type Ab2 scFv.
采用抗鼻咽癌单克隆抗体FC2对鼻咽癌患者外周血单个核细胞(PBMCs)进行体外免疫,并经EB病毒(EBV)转化。检测发现,10例鼻咽癌患者中,8例经FC2免疫并由EBV转化的B细胞产生了针对鼻咽癌的抗独特型抗体。通过RT-PCR扩增获得5种VH基因和7种VL基因,然后与(Gly4Ser)3接头连接形成14种scFv基因。用Sfi I酶切的scFv基因克隆到载体fUSE5中,并转化到大肠杆菌MC 1061中。获得了库容为1.5×10(8)个克隆的噬菌体抗独特型抗体库。经过四轮淘选,随机挑选270个噬菌体克隆,通过夹心ELISA获得91个FC2阳性克隆,阳性率为33.7%。通过结合抑制试验筛选出5个可能展示β型Ab2 scFv的克隆(D83、E92、G22、I50、I54)。对这5个噬菌体抗独特型抗体进行DNA测序进一步分析。G22、I50、I54的VDJ区分别属于VH4-39-D4-11-JH3-接头-V1-19-JL2、VH4-4-D4-11-JH6和VH4-31-D4-11-JH6。E92与G22的VDJ区相同;D83与I50的VDJ区相同。因此,通过体外免疫、EBV转化和噬菌体展示技术制备和筛选β型Ab2 scFv或CDR的策略是可行的,为利用β型Ab2 scFv制备癌症疫苗奠定了基础。